Novogen granted key phenoxodiol patent in US
19 November, 2003 by Graeme O'NeillSydney pharmaceutical company Novogen (ASX: NRT, NASDAQ: NVGN) has been granted a US patent covering all applications of its promising anti-cancer therapeutic phenoxodiol for benign and malignant cancers, including ovarian, breast, prostate and cervical cancers.
Agenix's D-dimer diagnostics get boost from international studies
19 November, 2003 by Graeme O'NeillTwo studies published recently in leading medical research journals have given ticks to the SimpliRED and Simplify blood-clot diagnostics developed by Brisbane biotech Agenix (ASX: AGX, NASDAQ: AGXLY)
Brain Resource Company raises $4 million, plans marketing push
19 November, 2003 by Melissa TrudingerSydney-based Brain Resource Company (ASX: BRC) has completed an AUD$4 million placement to institutional investors, giving it the funding to back a marketing push for its brain imaging and functional testing products and services.
Peptech settles Abbott dispute amicably
19 November, 2003 by Melissa TrudingerThe market responded favourably today to news that Peptech has reached an in principle agreement with Abbott to resolve its dispute over royalties for Abbott's anti-TNF alpha arthritis drug HUMIRA.
Genesis Biomedical and ENSI-MED to Merge
18 November, 2003 by Melissa TrudingerGenesis Biomedical (ASX: GBL) has signed a Heads of Agreement with ENSI-MED Manufacturing to acquire 100 per cent of the issued capital of the Canberra-based retractable syringe manufacturer.
GTG tightens patent grip
18 November, 2003 by Graeme O'NeillMelbourne company Genetic Technologies Ltd (ASX: GTG) has settled two of three lawsuits brought against US biotechnology companies for alleged infringements of its non-coding DNA gene-testing patents.
GM surgery to detoxify feed crop
17 November, 2003 by Graeme O'NeillMolecular geneticists at Melbourne University's Institute of Land and Food Resources plan to use RNA interference gene silencing to remove a potent neurotoxin from the manure and feed crop, vetch (Vicia sativa).
CEO change off the agenda at Ventracor AGM
14 November, 2003 by Andrew BirminghamShareholders at Ventracor's annual general meeting in Brisbane yesterday raised not a jot of concern about the board's surprise decision this week to replace CEO Michael Spooner with former Sirtex chief Colin Sutton.
Ex-Novartis CEO joins Pharmaxis
14 November, 2003 by Melissa TrudingerNewly-listed company Pharmaxis (ASX:PXS) has appointed ex-Novartis Australia CEO Gary Phillips as commercial director to look after sales and marketing efforts as the company prepares to complete clinical trials and roll out its first product.
AustCancer in gene test partnership
14 November, 2003 by Melissa TrudingerAustralian Cancer Technology (ASX:ACU) has partnered with Prof Ursula Kees at the Telethon Institute for Child Health Research to develop a diagnostic test able to rapidly screen tumour samples for deleted tumour suppressor genes.
Local researchers abuzz for bee genome publication
13 November, 2003 by Melissa TrudingerWith the honeybee genome about to be completed, work is ramping up in Assoc Prof Ben Oldroyd's laboratory at the University of Sydney to take advantage of the information it offers.
Bayer off the hook in NSW canola trial
12 November, 2003 by Graeme O'NeillNSW Agriculture Minister Ian MacDonald has advised Bayer CropScience that it will not have to destroy a trial crop of genetically modified herbicide-tolerant canola near Wagga, despite the discovery of a small number of canola plants in the surrounding buffer zone.
Premier in hunt for commercial partner
12 November, 2003 by Melissa TrudingerPremier Bionics (ASX:PBI) is ramping up its efforts to find a commercial partner for its Airway Clear sleep apnoea monitoring device.
Epitan: FDA intrigued by tanning drug
12 November, 2003 by Melissa TrudingerEpitan (ASX:EPT) has returned from its pre-IND meeting with the US Food and Drug Administration with a clear idea of what will be required to get approval for US clinical trials, according to CEO Wayne Millen.
Biotech veteran calls for tax breaks
12 November, 2003 by Melissa TrudingerLong time biotechnology investor Leon Serry has called on the federal government to implement a 100 per cent tax deduction as an incentive for significant institutional investment into Australian companies running Phase III clinical trials.
